← Steven A. Rosenberg

Papers by Steven A. Rosenberg

Page 2 · newest first

51. T-Cell Receptor Gene Therapy for Human Papillomavirus–Associated Epithelial Cancers: A First-in-Human, Phase I/II StudyJournal of Clinical Oncology · 2019
52. Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal CancersCancer Discovery · 2019
53. Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder CancerThe Journal of Immunology · 2019
54. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With GlioblastomaJournal of Immunotherapy · 2019
55. Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancersJournal of Clinical Investigation · 2019
56. Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal CancerCancer Immunology Research · 2019
57. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patientsNature Communications · 2019
58. Tumor-infiltrating human CD4 ⁺ regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivityScience Immunology · 2019
59. A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus–associated Epithelial CancersClinical Cancer Research · 2018
60. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapyJCI Insight · 2018
61. Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in MelanomaCancer Discovery · 2018
62. Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository ExperienceMolecular Therapy — Methods & Clinical Development · 2018
63. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHLBlood · 2018
64. T-cell Responses to TP53 “Hotspot” Mutations and Unique Neoantigens Expressed by Human Ovarian CancersClinical Cancer Research · 2018
65. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine modelJCI Insight · 2018
66. Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain MetastasesJournal of Immunotherapy · 2018
67. RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cellsScientific Reports · 2018
68. Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cellsScientific Reports · 2017
69. An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell ReceptorsMolecular Therapy · 2017
70. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II–Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3Journal of Clinical Oncology · 2017
71. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell TherapyMolecular Therapy · 2017
72. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancerScience · 2017
73. Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast CancerClinical Cancer Research · 2017
74. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 LevelsJournal of Clinical Oncology · 2017
75. LIGHT Elevation Enhances Immune Eradication of Colon Cancer MetastasesCancer Research · 2017
76. Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen SettingClinical Cancer Research · 2016
77. T-Cell Transfer Therapy Targeting Mutant KRAS in CancerNew England Journal of Medicine · 2016
78. Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell TransplantationBlood · 2016
79. A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell TherapiesHuman Gene Therapy Methods · 2016
80. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 ExpressionClinical Cancer Research · 2016
81. A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic MelanomaClinical Cancer Research · 2016
82. Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced MelanomaAnnals of Surgical Oncology · 2016
83. Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic MelanomaClinical Cancer Research · 2016
84. Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh TumorCancer Immunology Research · 2016
85. Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma.Journal of Clinical Oncology · 2016
86. Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor AntigensCancer Immunology Research · 2016
87. Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic MelanomaJournal of Clinical Oncology · 2016
88. MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 CasesJournal of Immunotherapy · 2016
89. Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase SystemMolecular Therapy · 2016
90. A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor CellsJournal of Immunotherapy · 2016
91. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host DiseaseJournal of Clinical Oncology · 2016
92. Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigensOncotarget · 2016
93. CCR 20th Anniversary Commentary: Autologous T Cells—The Ultimate Personalized Drug for the Immunotherapy of Human CancerClinical Cancer Research · 2015
94. Memory T cell–driven differentiation of naive cells impairs adoptive immunotherapyJournal of Clinical Investigation · 2015
95. Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic CancersJournal of Immunotherapy · 2015
96. Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic LeukemiaBlood · 2015
97. Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell TherapyBlood · 2015
98. Allogeneic T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor Cause Remissions of B-Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation without Causing Graft-Versus-Host DiseaseBlood · 2015
99. A Phase I study of an HLA-DPB1*0401-restricted T cell receptor targeting MAGE-A3 for patients with metastatic cancersJournal for ImmunoTherapy of Cancer · 2015
100. Immunogenicity of somatic mutations in human gastrointestinal cancersScience · 2015